Molbio Diagnostics Limited (Neutral)

Highlights

Molbio Diagnostics Limited (MDL) incorporated in 2000, is point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. They have developed Truenat platform, which is a novel POC polymerase chain reaction (PCR) platform that can operate in resource limited settings since its battery operated, facilitating decentralized diagnosis within an hour.

In addition to the above, through their subsidiary, Prognosys Medical Systems Private Limited, they offer digital imaging solutions, including radiology products such as ultraportable X-ray systems, mobile digital X-ray systems, floor-mounted and ceiling-suspended X-ray systems and C-arm systems, all under the brand ProRaD.

Truenat is patented in more than 100 countries for the diagnosis of multiple infectious and non-communicable diseases.  They operate in an oligopolistic market with high entry barriers, evidenced by the fact that their platform underwent 13 years of R&D to obtain Indian Council of Medical Research (ICMR) certification and Truenat test chip for diagnosing TB is the only one by an Indian company and one of the only two rapid molecular tests in the world, which has been endorsed by the World Health Organization for initial diagnosis of TB and rifampicin resistance detection using molecular diagnostic technology.

Out of the total proceeds of Rs. 9,400 mn, Rs. 1,778 mn would be go towards funding capex of the company, ~Rs. 221 mn would go towards general corporate purpose. Additionally, ~Rs. 7,400 mn going towards promoter & investor selling shareholders of the company.  

Key Highlights

• The total addressable market for global POCT currently stood at USD 29.3 bn (equivalent to Rs. 2,589 bn) (infectious and non-infectious diseases) and is projected to grow at CAGR of 17.9 pct between 2025-30 to be a USD 67.1 bn (equivalent to Rs.  5,928 bn) market by 2030.

• MDL is focused on strengthening capabilities and expanding offerings through strategic acquisitions and collaborations with various organizations. In March 2023, the company acquired Prognosys which offers X ray services. Further, October 2024, MDL invested in OptraScan INC which provides digital pathology solutions, offering a range of digital pathology scanners, AI-powered analysis tools, and telepathology services.
• MDL operates 6 manufacturing facilities in India. Including Prognosys, MDL capacity in FY26 stood at 5,400 devices per annum and 39,000,000 Trudent test kits per annum with capacity utilization of 42.3 pct and 58.25 pct. Indicating that their manufacturing infrastructure is prepared for future growth since they made early investments in it.
• Their vertical integration strategy allows them to bring healthcare innovations to market rapidly by streamlining the process from R&D to production, sales, and marketing. Through this approach, they combine design expertise, regulatory capabilities, and production know-how to drive impactful advancements in the diagnostic industry.
• MDL’s key growth strategies include (i) To expand geographical presence in India and across the globe (ii) To expand suite of diagnostic solutions for multiple diseases (iii) Develop new POC platforms for other communicable and non-communicable diseases. (iv) Grow through strategic acquisitions and alliances and establish a centre of excellence.
• The sales of the company have grown by 31 pct CAGR over FY24-26 and EBITDA/profit has grown 33 pct CAGR/40 pct CAGR over same year. In FY26 the company reported sales of Rs. 14,457 mn driven by healthy growth in sales of test kits and devices. EBITDA of the company increased 28 pct YoY to Rs. 3,282 mn while margins slipped on higher other expenses. In FY26 the company posted profit of Rs. 1,641 mn, up 18 pct YoY.

Key Risk

• The company might face client concentration risk, as 80 pct of company’s sales came from Central government (56.52 pct) and state government (23.29 pct).
• Any product liability claims or regulatory actions or imposition of liquidated damages on account of failure to meet the contractual obligations, could have an adverse effect on MDL’s business,
• MDL operations are subject to extensive government regulation and if we fail to obtain, maintain or renew statutory and regulatory licenses, permits and approvals, can adversely affect their business.

Financial Performance

Source: – RHP.

Peer Comparison based on FY26 Financials.

Valuation

Molbio is an innovative point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid, and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. Their flagship innovation, Truenat, is a novel POC polymerase chain reaction (PCR) platform that is battery-operated and can operate in resource-limited settings, facilitating decentralized diagnosis within an hour. At the upper end of the price band of Rs. 807, the issue is priced at an EV/EBITDA of 28.5x its FY26 post issue capital. The issue appears to be fully priced.

Disclaimer: The views shared in blogs are based on personal opinions and do not reflect the company’s views. Investment involves risk, and it is advisable to consult a financial advisor before making any investment through the app. The decision to invest is solely that of the investor, and the company or its communication cannot be held responsible for it.